MGMT Levels and Response to Temozolomide in Melanoma
Author Information
Author(s): MR Middleton, JM Lunn, C Morris, G Rustin, SR Wedge, MH Brampton, MJ Lind, SM Lee, DR Newell, NM Bleehen, ES Newlands, AH Calvert, GP Margison, N Thatcher
Hypothesis
The study investigates whether pretreatment levels of MGMT in melanoma biopsies can predict response to temozolomide treatment.
Conclusion
Measurements of pretreatment levels of MGMT in melanoma did not predict for response to temozolomide.
Supporting Evidence
- Among 50 evaluable patients, there were three complete responses, four partial responses, six with stable disease, and 37 with progressive disease.
- The overall response rate was 14%.
- In 33 patients, there was no significant difference in pretreatment MGMT levels between those who responded to temozolomide and those who did not.
Takeaway
The study looked at whether a certain protein level in melanoma tumors could help doctors know if a medicine would work, but it turns out it doesn't help at all.
Methodology
Patients with advanced melanoma were treated with temozolomide, and their tumor MGMT levels were measured to see if there was a correlation with treatment response.
Limitations
The study had a small sample size and included patients with prior chemotherapy, which may have affected the results.
Participant Demographics
56 patients, 46% men and 54% women, with a WHO performance status of 0 to 3.
Statistical Information
P-Value
0.95
Statistical Significance
p = 0.95
Want to read the original?
Access the complete publication on the publisher's website